New Study Identifies Chemical Inhibitors to Block Cancer Cell Growth

Overview of the Research

A recent study published in the journal Nature Letters has unveiled a set of chemical inhibitors capable of halting cancer cell proliferation while sparing normal cells. One of the primary characteristics of cancer is the disruption of the cell cycle, a crucial process that governs the timing and frequency of cell division.

Understanding the Cell Cycle

The cell cycle is regulated by various proteins that typically manage the activation and deactivation of cell division based on tissue requirements. Disruptions in the proteins that control this cycle can lead to abnormal cell division, allowing cells to multiply uncontrollably and ultimately contribute to cancer development. Consequently, targeting the cell cycle has long been recognized as a powerful strategy to mitigate cancer growth.

Proliferative Block as an Alternative

Unlike traditional chemotherapy, which often causes genetic damage and affects both cancerous and healthy cells, imposing a proliferative block on the cell cycle offers a promising alternative. This approach can trigger cellular senescence, a condition where cells exit the cell cycle and stop dividing. A critical question arises: can we selectively induce senescence in cancer cells without impacting normal cells?

Insights from Australian Researchers

Researchers from the Walter and Eliza Hall Institute (WEHI), the Cancer Therapeutics Cooperative Research Centre, and the University of Melbourne in Australia leveraged earlier findings that identified the protein KAT6A as a suppressor of cellular senescence. They hypothesized that pharmacological inhibition of KAT6A could effectively induce senescence in cancer cells. Their findings were published in Nature Letters.

Experimental Results

In a mouse model of lymphoma, a type of blood cancer, the deletion of KAT6A resulted in a significant extension of lifespan for mice diagnosed with cancer. Encouraged by these promising results, the research team collaborated with medicinal chemists to meticulously screen hundreds of thousands of chemical compounds to discover inhibitors targeting KAT6 proteins.

Promising Compounds Under Investigation

The study revealed that the identified compounds were highly effective in inducing cellular senescence in lymphoma cancer cells and inhibiting their growth by obstructing KAT6 function. Importantly, these compounds do not cause DNA damage and do not harm normal cells, making them considerably less toxic than conventional chemotherapy treatments currently in use. Due to the remarkable initial outcomes, the KAT6 inhibitors, specifically WM-8014 and WM-1119, are now the focus of intense research.

Conclusion

This innovative approach to targeting cancer cell proliferation holds significant potential for developing more effective and less toxic cancer therapies.

Reference

Baell, J. B., Leaver, D. J., Hermans, S. J., Kelly, G. L., Brennan, M. S., Downer, N. L., . . . Thomas, T. (2018). Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. Nature, 560(7717), 253-257. doi:10.1038/s41586-018-0387-5